Adequan® i.m. Shortage Expected

VaccinationDue to renovations at Luitpold Pharmaceuticals Inc.’s Shirley, N.Y.-based factory, supplies of Adequan® i.m., the only polysulfated glycosaminoglycan (PSGAG) approved by the Food and Drug Administration (FDA), are expected to be limited over the coming months.

The factory in NY has undergone a significant renovation to meet enhanced quality standards and address observations of the FDA. This has resulted in the depletion of existing inventories. The company has carefully managed its supply to allocate inventory optimally, but the product will be out of stock for a short period of time. It expects to resume shipments of the 5 mL product in early July, followed by the 50 mL in August.

The company expressed appreciation for the patience and loyalty of its customers during the supply interruption. Luitpold plans to continue its active role in supporting the veterinary and horse owner industry through sponsorships and educational programs. Representatives stated that its commitment to the health and well-being of these magnificent animals remains the primary focus.

Since approved for use in the horse by the FDA in 1984, no other PSGAG has been developed to treat non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. There is no generic Adequan® i.m. product available anywhere in the world, and Luitpold recommends careful evaluation of any alternative product claims to ensure safety and efficacy.

For the most recent updates on expected release dates of product, visit and

Territory managers will continue to communicate these updates to both their veterinary accounts, as well as many of the horse owners they meet at sponsored events.

You can also call the customer service department at 1-800-458-0163 or Allyn Mann at 816-590-5032 for the most current information.